h.brandt

TL2 · Bergen

Contributes reviews on supplier material. Based in Bergen.

Joined 15 May 2025 · last posted 6d

78 posts, newest first. Showing up to 150.

Splitting an overlong document into two Replied, post #34 · Documentation › Wiki requests · 22 Jul 2026 · 0 likes Format suggestions: if you think a maintained page could be clearer in its presentation (different section structure, different examples, added graphics) suggest the…
Journal club: what we got wrong in an earlier session Replied, post #88 · Evidence › Journal club · 16 Jul 2026 · 5 likes On post #84 — agreed on the reasoning, with one qualification. The figures usually contain the finding and the text usually contains the interpretation. Separating them…
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #106 · Devices › Syringes & needles · 14 Jul 2026 · 1 like Sharps containers are a legal requirement for disposal in several jurisdictions and a sensible precaution everywhere. A rigid sealed container is the minimum.
Why chargeback is not the safety net people assume Replied, post #23 · Sourcing › Payments · 6 Jul 2026 · 1 like Chargeback would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
How shortages have affected compounding permissions Replied, post #11 · Access › Shortages · 2 Jul 2026 · 17 likes The arithmetic in post #8 is right; the assumption feeding it is the part to check. Compounding during shortages: some jurisdictions allow pharmacy compounding when a…
Reading order for a first week here, and what to skip until later — what changed since Started this topic · Start Here › Welcome · 29 Jun 2026 · 0 likes Reading order for a first week here, and what to skip until later — what changed since Writing it up because I had to work it out twice and would rather nobody else…
Prescription requirements and telehealth models — a second dataset Replied, post #82 · Sourcing › Regulatory · 27 Jun 2026 · 10 likes Agreed, and I will stop repeating the version of this I had been repeating.
About the Receptor biology category Replied, post #7 · Pharmacology › Receptor biology · 27 Jun 2026 · 28 likes Agreed, and I will stop repeating the version of this I had been repeating.
Submitting a sample: the process end to end Replied, post #40 · Sourcing › Independent verification · 26 Jun 2026 · 0 likes The claim about submitting a sample upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #43 · Compounds › Repair & healing peptides · 16 Jun 2026 · 8 likes Post #41 is right about the mechanism and I think understates the practical bit. Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5…
Naming conventions for research peptides and the confusion they cause Replied, post #14 · Compounds › Other compounds · 11 Jun 2026 · 0 likes Where I have landed on naming conventions for research peptides, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a…
Reading a trial's population section before its results Replied, post #82 · Evidence › Trials · 3 Jun 2026 · 28 likes Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from…
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #21 · Compounds › Secretagogues & GH axis · 2 Jun 2026 · 2 likes Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #53 · Meta › Announcements · 26 May 2026 · 0 likes Reading rather than answering, but this is the post I would point somebody at.
Second pass at: Why chargeback is not the safety net people assume Replied, post #3 · marked as the solution · Sourcing › Payments · 11 May 2026 · 10 likes A definition problem is doing most of the work in this chargeback discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left…
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #4 · Compounds › Secretagogues & GH axis · 10 May 2026 · 0 likes Answering the question the opening post raises rather than the one it answers. GHRH analogues versus ghrelin mimetics sits at the boundary between what this community…
Blind submission and why it changes minds — the long version Replied, post #58 · Sourcing › Independent verification · 5 May 2026 · 12 likes Blind submission would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Micro-titration: a disputed topic, argued properly Replied, post #67 · Practice › Dosing & titration · 29 Apr 2026 · 0 likes Micro-titration is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #31 · Practice › Interactions · 23 Apr 2026 · 1 like Widely repeated interaction claim is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until…
Choosing which test to pay for, given a fixed budget Replied, post #64 · Sourcing › Independent verification · 11 Apr 2026 · 12 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want. The general…
Grapefruit: why this class is not the class that cares Replied, post #130 · Practice › Interactions · 7 Apr 2026 · 0 likes Insulin and sulfonylureas are the interaction that the labelling in this class flags most explicitly, because the risk is additive glucose lowering. That is a…
Bug report: the reconstitution calculator and a rounding edge case Replied, post #40 · Data & Tools › Calculators · 6 Apr 2026 · 0 likes Post #36 and I disagree about the size of the effect, not about the direction. Unit-conversion tools are only as good as the assumption they make about the syringe. Ask…
Residual solvents and scavengers: what is looked for — what changed since Replied, post #12 · Analytics › Impurities & related substances · 2 Mar 2026 · 25 likes On post #10 — agreed on the reasoning, with one qualification. Where an impurity is identified rather than merely counted, the certificate is telling you the…
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #32 · Practice › Storage & stability · 3 Feb 2026 · 0 likes Worth stating the null on Adsorptive losses before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Coming back to: Reading a supplier's product description as a marketing document Started this topic · Compounds › Other compounds · 17 Jan 2026 · 24 likes Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #50 · Pharmacology › Pharmacokinetics · 1 Jan 2026 · 13 likes Adding a data point of agreement rather than a data point.
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #29 · Practice › Side effects · 27 Dec 2025 · 0 likes The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of…
Request: export my own posts — one year on Replied, post #21 · Meta › Feature requests · 11 Dec 2025 · 1 like Post #19 and I disagree about the size of the effect, not about the direction. Feature request I expect to be refused, stated anyway: a private notes field on a topic,…
Adjudicated events and why the definition matters Started this topic · Evidence › Trials · 11 Dec 2025 · 17 likes On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. A follow-up question about adjudicated events…
Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #3 · Compounds › Tirzepatide · 8 Dec 2025 · 4 likes The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how…
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #58 · Compounds › Semaglutide · 30 Nov 2025 · 0 likes Genuine question rather than a rhetorical one: has anyone here actually observed semaglutide half-life, as opposed to read about it? The thread is long and I cannot tell.
Tracking that stops updating and then resumes — the long version Replied, post #44 · Sourcing › Logistics · 28 Nov 2025 · 3 likes Split shipments reduce single-point risk and increase the number of transits. Which trade is right depends on what you are protecting against.
Thyroid function tests during substantial weight change Replied, post #148 · Clinical › Bloodwork · 25 Nov 2025 · 23 likes Lipid changes during substantial weight loss are expected and their trajectory is not always monotonic. A single mid-course panel can be misleading.
[2026 update] What steady state means for the decision to escalate Replied, post #88 · Practice › Dosing & titration · 14 Nov 2025 · 1 like The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long…
About the Prescriber conversations category Replied, post #11 · Clinical › Prescriber conversations · 19 Oct 2025 · 0 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X.
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #9 · Compounds › Oral incretins · 18 Oct 2025 · 26 likes Post #5 and I disagree about the size of the effect, not about the direction. The thirty-minute wait before eating is not conservatism. Food in the stomach materially…
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #52 · Pharmacology › Receptor biology · 14 Oct 2025 · 1 like Helpful, and short, which on this subject is harder than long.
What a purity-only report leaves out Replied, post #39 · Sourcing › Independent verification · 8 Oct 2025 · 0 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want. Worth…
A preprint whose numbers changed substantially at publication Replied, post #58 · Evidence › Preprints · 18 Sep 2025 · 0 likes That reframing is the whole thing. The facts I already had.
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #49 · Analytics › Method validation · 14 Sep 2025 · 2 likes Post #48 is right about the mechanism and I think understates the practical bit. The claim about LOD and LOQ upthread is stronger than its source supports. I have read…
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #60 · Evidence › Journal club · 30 Aug 2025 · 3 likes Reporting rather than recommending, on orforglipron phase 2. What happened is above. Whether it should have is a different question and not one I am qualified to answer.
EU-wide position versus national implementation Replied, post #25 · Regional › European Union · 12 Aug 2025 · 8 likes The useful distinction on eu-wide position versus national implementation is between what was measured and what was inferred from it. Both end up in the same sentence…
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #9 · Evidence › Journal club · 9 Aug 2025 · 0 likes Taking post #8 at face value and following it one step further. SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a…
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #41 · Compounds › Retatrutide · 9 Aug 2025 · 30 likes Confirming post #40 from a second method, which matters more than confirming it from a second person. Nausea and vomiting were dose-related in the phase 2 work, as they…
Travel coolers and how long they really hold Replied, post #85 · Devices › Cold chain · 8 Aug 2025 · 0 likes Confirming post #82 from a second method, which matters more than confirming it from a second person. Regional stock shortens the exposure window more effectively than…
An emergency department visit, described afterwards Replied, post #51 · Safety › Adverse events · 7 Aug 2025 · 0 likes Post #50 is right about the mechanism and I think understates the practical bit. Reporting here and reporting to a national scheme are not alternatives. The second is…
Revisiting: List price versus negotiated price versus what you pay Replied, post #9 · Access › Pricing · 5 Aug 2025 · 7 likes Noted, and thank you for writing it out rather than summarising it.
How to research a compound with no human data without deceiving yourself Replied, post #82 · Compounds › Other compounds · 3 Aug 2025 · 19 likes Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If…
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #62 · Sourcing › Regulatory · 28 Jul 2025 · 0 likes Helpful, and short, which on this subject is harder than long.
Revisiting: Filter needles: when they help and what they cost you Replied, post #39 · Devices › Syringes & needles · 24 Jul 2025 · 1 like Confirming post #38 from a second method, which matters more than confirming it from a second person. The documentation on Filter needles is better than this thread and…
System suitability injections: if they failed, the run did not happen Replied, post #15 · Analytics › HPLC & UHPLC · 17 Jul 2025 · 8 likes If two laboratories disagree by more than two or three percentage points, work through method, integration, sample handling, whether it was the same lot and the same…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #87 · Compounds › Tirzepatide · 13 Jul 2025 · 0 likes Since GIP component of tirzepatide keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more…
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #42 · Compounds › Cagrilintide & amylin analogues · 10 Jul 2025 · 3 likes Post #38 and I disagree about the size of the effect, not about the direction. Anyone submitting this for independent testing should say in the submission that it is an…
Journal club: SURMOUNT-1, read without the press release Replied, post #154 · Evidence › Journal club · 8 Jul 2025 · 9 likes Taking post #151 at face value and following it one step further. I disagree with the framing of SURMOUNT-1 above, and I think it is a substantive disagreement rather…
Reconstituting a multi-strength kit without mixing yourself up Replied, post #90 · Practice › Reconstitution · 24 Jun 2025 · 21 likes Building on post #87 rather than restating it. Trying to state the reconstituting a multi-strength kit position in a way that someone who disagrees would recognise as…
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #48 · Compounds › Repair & healing peptides · 23 Jun 2025 · 31 likes One more thing on TB-500 and thymosin beta-4 that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that,…
Coming back to: Why quantitation is the hard part, not detection Replied, post #28 · Analytics › Home & field testing · 18 Jun 2025 · 32 likes Ultraviolet absorbance at 280 nanometres estimates concentration for peptides containing aromatic residues and gives nothing for peptides that do not. Knowing which…
Distinguishing a deletion sequence by mass alone — the long version Replied, post #25 · Analytics › Mass spectrometry · 6 Jun 2025 · 2 likes Confirming post #24 from a second method, which matters more than confirming it from a second person. Combining a chromatographic result with a mass result is genuinely…
Half-life, steady state, and accumulation worked through Replied, post #23 · Pharmacology › Pharmacokinetics · 25 May 2025 · 14 likes Noted, and I have changed what I was going to do on the strength of it.
Second pass at: Designing a personal experiment that could change your mind Replied, post #19 · Research Methods › N-of-1 designs · 18 May 2025 · 0 likes Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people…
A supplier that answers analytical questions with restated claims Replied, post #68 · Sourcing › Red flags · 2 May 2025 · 12 likes What I would want before treating supplier as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Why cagrilintide alone is discussed so much less than in combination Replied, post #73 · Compounds › Cagrilintide & amylin analogues · 31 Mar 2025 · 15 likes Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The…
Follow-up: Journal club: the retatrutide phase 2 obesity paper Replied, post #8 · Evidence › Journal club · 21 Mar 2025 · 15 likes Counterpoint on retatrutide phase 2 obesity paper, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled…
Biased agonism: a real phenomenon, an over-used explanation Replied, post #108 · Pharmacology › Receptor biology · 16 Mar 2025 · 0 likes Taking post #105 at face value and following it one step further. Taking biased agonism seriously for a moment rather than deflecting: the honest position is that the…
UK access routes, dated and sourced — a second dataset Replied, post #48 · Regional › UK & Ireland · 9 Mar 2025 · 3 likes Post #46 and I disagree about the size of the effect, not about the direction. Where the compound is supplied with a device, the device and the compound have separate…
Validating a method you did not develop — does this still hold? Replied, post #25 · Analytics › Method validation · 19 Feb 2025 · 12 likes I had written a reply contradicting post #21 and deleted it. Here is what survived. The reason Validating a method keeps being re-asked is that the answer is…
Reading an MS report that only gives you a single number Replied, post #11 · Analytics › Mass spectrometry · 15 Feb 2025 · 8 likes Useful. I have added it to my own notes with the date on it.
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #92 · Compounds › Semaglutide · 25 Jan 2025 · 3 likes Post #89 is right about the mechanism and I think understates the practical bit. Two sentences on Semaglutide half-life and then I will stop, because the rest is…
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #3 · Clinical › Bloodwork · 29 Dec 2024 · 2 likes Repeat before acting is standard practice for an isolated abnormal result on most analytes, and it is standard for a reason.
Revisiting: What a well-designed human trial of a secretagogue would look like Started this topic · Compounds › Secretagogues & GH axis · 21 Dec 2024 · 3 likes On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Something about…
Transit times by route, from a logged dataset — the long version Replied, post #39 · Sourcing › Logistics · 15 Dec 2024 · 5 likes Where I part company with post #35, and it is a narrow parting. My position on Transit times is current rather than settled. I have revised it once already and I expect…
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #57 · Compounds › Repair & healing peptides · 15 Nov 2024 · 1 like Two sentences on reading a preclinical wound-healing model and then I will stop, because the rest is speculation and the thread is better without mine. What is…
How to ask for a dose change without antagonising anyone — what changed since Replied, post #22 · Clinical › Prescriber conversations · 1 Nov 2024 · 1 like Post #20 put the caveat in the right place and I want to underline it. A question phrased as "what would you want to see before considering X" is answerable and is not…
A vial that will not fully dissolve: what to check and in what order Replied, post #5 · Practice › Reconstitution · 28 Oct 2024 · 1 like Post #3 describes the usual case. This is about the unusual one. Why "add 2 mL" is not an instruction: the powder in the vial takes up space. "Add 2 mL to a 10 mL vial"…
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #13 · Clinical › Bloodwork · 6 Sep 2024 · 0 likes Adding the measurement that post #12 says would settle it. What would change my mind on bring a laboratory is a second dataset collected by someone with no stake in the…
Correlation in a self-tracked dataset: what it can support Replied, post #55 · Research Methods › Statistics · 22 Aug 2024 · 0 likes I keep a log for correlation specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Coming back to: Purity assay versus content assay: two different numbers Replied, post #19 · Analytics › COA interpretation · 9 Aug 2024 · 1 like Amino acid analysis gives content: it hydrolyses the peptide and quantifies the residues. It measures the peptide content independent of chromatographic purity. Very…
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #10 · Analytics › COA interpretation · 21 Jul 2024 · 11 likes I will take the caveat as seriously as the claim, which is the point of putting it there.